Speedy US approval for Novartis' Tabrecta
admin 6th May 2020 Uncategorised 0The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option
More: Speedy US approval for Novartis' Tabrecta
Source: News
The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option
More: Speedy US approval for Novartis' Tabrecta
Source: News
© 1994 - 2026 B.M. Pharmaceuticals